62 results about "Bone lesion" patented technology

Methods and systems for evaluating bone lesions include accessing a first dataset acquired from a patient with a first imaging modality and a second dataset acquired from the patient with a second imaging modality. A segmentation is performed on the first dataset to identify a subset of the first dataset corresponding to a skeletal structure of the patient and a patient skeletal metric representing a total bone volume of the patient is automatically calculated from the subset of the first dataset. The methods and systems further include detection of at least one lesion in the second dataset, classification of the at least one lesion as a bone or non-bone lesion, automatic calculation of a bone lesion metric based on the classification, and calculation of a lesion burden as a ratio of the bone lesion metric and the patient skeletal metric.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3/FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease.

The invention discloses a whole-body bone imaging bone segmentation method based on atlas registration. The method comprises the following steps: acquiring original whole-body bone imaging data collected by professional equipment; subjecting the original whole-body bone imaging data to preprocessing including pollution detection processing, pollution repair processing, standardization processing,registration processing and regularization processing; and according to a deformation segmentation template stored in the system, carrying out segmentation processing on the preprocessed whole-body bone development image to obtain a segmentation result of whole-body bone development. By means of the method, bone positioning can be conducted on an image obtained through single whole-body bone scanning examination, a basis is provided for bone lesion positioning, development quality is improved by automatically reducing a difference through bone development pollution detection and a pollution repair algorithm, and the development difference between different whole-body bone scans is solved; and rapid, accurate and intelligent positioning of the whole-body bone imaging skeleton is achieved.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3/FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease reduce tumor burden in multiple myeloma and to block bone disease.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3/FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease.

A composite medicine for preventing and treating the retrograde bone lesion, osteoporosis and osteoarthrodynia contains vegetable estrogen (30-50%) and aminoglocose (50-70%), and is prepared through extracting the vegetable estrogen from relative plant, preparing the aminoglocose hydrochloride (or sulfate) from the the shell of shrimp and crab or the chitin, and conventionally preparing said medicine. Its advantages are high curative effect and no toxic by-effect.

The invention discloses a spinal closed puncture guide, which can be specifically used for the puncture positioning of various parts of the spinal column such as intervertebral foramen, intervertebral disc, articular process and pedicle. It consists of an angle ruler, a ruler, a puncture needle guide, a positioning needle needle guide, an aiming ruler, a puncture needle and a positioning needle, the angle ruler is in the shape of a semi-circle, and the ruler slides vertically through the angle ruler , and can be locked by the angle ruler, the puncture needle guide is provided with two pieces, which are respectively slid on both ends of the angle ruler, and can be locked at any angle of the angle ruler, the two puncture needle guides no matter from the angle Any angle of the ruler guides the puncture needle to the same point on the center line of the angle ruler. The positioning needle needle guide is provided with two pieces, one is fixed on one end of the ruler, and the other is slid on the other side of the ruler. One end can be locked, and the positioning needle guide device guides the positioning needle to stick to the bone near the patient's lesion.

The invention relates to a filling stent material containing a three-layer structure and suitable for bone repairing and a preparation method of the filling stent material. The bottom end of a bone repairing stent has a multi-stage pore structure with high porosity, can slowly release bioactive factors and improve the inflammatory state of a bone lesion portion, has good biological activity and bone induction ability, and is beneficial to enhancing osteogenesis and bone remodelling; and an upper end is a bone cement matrix barrier layer with low porosity, and a middle layer is an adhesive layer. The composite stent provided by the invention utilizes a barrier effect of an upper layer and an osteogenesis promoting effect of a lower layer, and can effectively promote repairing and regeneration of bone tissues; and besides good adhesion and filling effects, the filling gel auxiliary material also has a bone growth promoting component, and has a synergistic effect with a skeleton.

The invention discloses a method of complementing a diseased bone to obtain a bone expected reference model. The method has the technical effects that the complementing form after bone lesion removalcan be quickly obtained, and the complementing form is basically close to natural bones; the method is not limited by complementation when the range of lesions is too large; and under the condition that clinical data and operator experience can not be considered, the trained model and the method can also be copied, and basic bone completion is completed. Therefore, the technical difficulty of theskeleton expected reference model is reduced, the manufacturing efficiency of the skeleton expected reference model is improved, and technical popularization and copying are facilitated.

Instrumentation sets and methods for preparing and implanting an osteochondral allograft to a bone lesion. Instrumentation sets include a pair of guide blocks, a recipient guide block and an allograft guide block, for preparing a cavity at the bone lesion matched by a similarly sized and shaped allograft. Guide blocks provide simple and direct techniques for preparing a matching cavity, formed at the bone lesion, to a bone implant, to be secured within the cavity. Methods include use of the instrumentation to restore bone surfaces for any number of sites using any allograft source. In some cases, the bone lesion is in a humeral head and the allograft source is a talus.

The invention discloses plaster for treating wind-cold-dampness arthralgia arthritis and bone lesion. Raw materials comprise a fried group and a fine group. The fried group comprises, by weight parts, 50-100 parts of dog bone, 50-100 parts of tortoise shell and 30-80 parts of mole cricket. The fine group comprises, by weight parts, 100-150 parts of chili powder and 60-120 parts of thuja sutchuenensis. The plaster is used for treating wind-cold-dampness arthralgia arthritis and bone lesion and has the advantages of being good in curative effect, taking effect quickly and being convenient to use.

The present invention pertains to an implant for treatment of a bone lesion site, the implant including a polymer porous film and a layer containing a biocompatible material, wherein the polymer porous film is a polymer porous membrane of a three-layer structure having a porous surface layer A, a porous surface layer B, and a macrovoid layer interposed between the surface layer A and the surface layer B; the average pore diameter of the pores in surface layer A is smaller than the average pore diameter of the pores in surface layer B; the macrovoid layer has a partition joined to the surface layers A and B and a plurality of macrovoids enclosed by the partition and the surface layers A and B; and the pores in the surface layers A and B communicate with the macrovoids.

The invention, relating to the field of traditional Chinese medicine, discloses an externally dressed drug for treating fracture, solving the problems of bad curative effects, slow effect and the like in the prior art by combining modern pharmacological studies based on pathologic knowledge of fracture in traditional Chinese medicine. The drug comprises the following ingredients: 20-60 weight parts of eupolyphaga sinensis, 5-25 weight parts of dragon's blood, 15-40 weight parts of cassia twig, 15-25 weight parts of olibanum, 10-20 weight parts of rhizoma anemarrhenae, 5-15 weight parts of rhizoma corydalis, 10-20 weight parts of myrrh, 5-15 weight parts of cinnabar, 10-30 weight parts of achyranthes bidentata, 5-20 weight parts of pillis ophidiae, and 20-50 weight parts of Panax notoginseng powder. The drug of the invention is used for fracture and bone lesions. After fracture patients use the drug, the wound heals quickly without recurrence, the swelling is reduced quickly, and the pain is alleviated. After the fractures are healed, there is no side effect, and limbs can move normally.

Pharmaceutical compositions for treating bone lesions in multiple myeloma or pharmaceutical compositions for treating multiple myeloma which contain as an active ingredient a compound having both of an effect of suppressing bone resorption accompanying multiple myeloma and an effect of inhibiting multiple myeloma, more particularly, 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or its salt.

The present invention refers to an osteochondral local prosthetic insert for partial humeral joint reconstitution by reconstitution of the bone anatomical sphericity to treat bone lesions, in particular Hill-Sachs lesions. The local osteochondral prosthetic insert is a rigid monolithic body having a truncated-cone shape, the proximal diameter greater than the distal diameter, the proximal end of convex shape and rounded at the corners, and a tapered distal end. The lateral surface of the insert shows in the middle-distal part a non-return shaping that allows the maintenance of the position defined in the surgical operation. The proximal end is convex in order to better adapt to the local bone sphericity and has recesses for the manipulation and positioning through dedicated tools.

The invention, which belongs to the field of medical technology, discloses a combined bone tumor minimally-invasive incision biopsy device and a control method thereof. The device comprises a camera module, a lesion prediction module, a main control module, a lesion distribution detection module, a searchlighting module, a slicing module, a drilling module, and a sew-up module. According to the invention, with the lesion prediction module, a database is established by collecting historical lesion data of users having different types of malignant lesions and thus a proportional risk function isestablished; conversion and missing value filling are carried out on data of to-be-detected user; the filled numbers are substituted into the proportional risk function and a lesion prediction modelis established, so that the lesion prediction is carried out accurately and the usage needs of users are met. Meanwhile, the lesion distribution detection module can accurately determine the lesion distribution area, thereby improving the position accuracy of the operation and improving the surgical effect.